News | August 09, 2023
Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The inspection closed with zero observations and a classification of No Action Indicated
JDHL has a strong reputation as an end-to-end design-focused manufacturer of electro-medical devices
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
This product will be launched through Granules Consumer Health (GCH) division
Subscribe To Our Newsletter & Stay Updated
